Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ORMP 
Oramed Pharmaceuticals Inc (ORMP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ORMP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -66.91% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 94.58M USD | Price to earnings Ratio 4.55 | 1Y Target Price 3.25 |
Price to earnings Ratio 4.55 | 1Y Target Price 3.25 | ||
Volume (30-day avg) 142152 | Beta 1.77 | 52 Weeks Range 1.96 - 3.09 | Updated Date 03/30/2025 |
52 Weeks Range 1.96 - 3.09 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.51 |
Earnings Date
Report Date 2025-03-04 | When After Market | Estimate 0.02 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -4.12% | Return on Equity (TTM) 2.89% |
Valuation
Trailing PE 4.55 | Forward PE - | Enterprise Value -55693294 | Price to Sales(TTM) 141.54 |
Enterprise Value -55693294 | Price to Sales(TTM) 141.54 | ||
Enterprise Value to Revenue 2.86 | Enterprise Value to EBITDA 0.52 | Shares Outstanding 40769000 | Shares Floating 33658562 |
Shares Outstanding 40769000 | Shares Floating 33658562 | ||
Percent Insiders 10.62 | Percent Institutions 17.32 |
Analyst Ratings
Rating 3 | Target Price 3.25 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Oramed Pharmaceuticals Inc
Company Overview
History and Background
Oramed Pharmaceuticals Inc. was founded in 2006. The company is focused on developing oral insulin capsules for the treatment of diabetes. A major milestone was the development and clinical testing of its lead product, ORMD-0801. The company has evolved from preclinical studies to Phase 2 and Phase 3 clinical trials.
Core Business Areas
- Oral Insulin Development: Oramed's primary focus is the development and commercialization of ORMD-0801, an oral insulin capsule designed to improve glycemic control in patients with diabetes.
- Clinical Trials: Conducting clinical trials to assess the safety and efficacy of ORMD-0801 and potentially other oral therapies.
Leadership and Structure
Nadav Kidron is the CEO of Oramed Pharmaceuticals. The company has a management team overseeing clinical development, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- ORMD-0801: ORMD-0801 is an oral insulin capsule in Phase 3 clinical trials for treating type 2 diabetes. Market share is currently 0% due to the product not being commercially available. Competitors include Novo Nordisk (NovoLog, Insulin Tresiba, Ozempic), Eli Lilly (Humalog, Trulicity), and Sanofi (Lantus, Toujeo).
Market Dynamics
Industry Overview
The diabetes treatment market is large and growing, driven by increasing prevalence of diabetes globally. The industry is characterized by intense competition and continuous innovation.
Positioning
Oramed aims to disrupt the insulin market by offering an oral alternative to injections. Its competitive advantage lies in its novel oral delivery technology.
Total Addressable Market (TAM)
The global diabetes market is projected to reach hundreds of billions of USD. Oramed is positioned to capture a share of this market if ORMD-0801 is successfully commercialized.
Upturn SWOT Analysis
Strengths
- Novel oral insulin delivery technology
- Potential to improve patient compliance and quality of life
- Strong intellectual property portfolio
Weaknesses
- Reliance on successful clinical trial outcomes
- Limited financial resources compared to larger pharmaceutical companies
- Product is not yet commercialized
Opportunities
- Growing global diabetes market
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established insulin products and new therapies
Competitors and Market Share
Key Competitors
- NVO
- LLY
- SNY
Competitive Landscape
Oramed faces significant competition from established insulin manufacturers. Oramed aims to be the main competitor in the oral insulin market.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by preclinical results and advancement in clinical trials.
Future Projections: Future growth depends heavily on the successful completion of Phase 3 trials and subsequent regulatory approval for ORMD-0801. Analyst projections vary widely depending on the perceived probability of success.
Recent Initiatives: Recent initiatives include patient enrollment in Phase 3 trials and exploring potential partnerships.
Summary
Oramed Pharmaceuticals is a development-stage pharmaceutical company with a promising oral insulin technology. Success hinges on positive clinical trial outcomes, which could disrupt the diabetes treatment market. Currently, the company is high risk due to dependence on successfull trials. Oramed must be mindful of larger competitors and potential regulatory hurdles in the process to getting the product approved.
Similar Companies
- NVO
- LLY
- SNY
Sources and Disclaimers
Data Sources:
- Oramed Pharmaceuticals Inc. Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oramed Pharmaceuticals Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2006-04-21 | President, CEO & Executive Chairman Mr. Nadav Kidron Esq. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.oramed.com |
Full time employees - | Website https://www.oramed.com | ||
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.